Variables |
SVR no.(%) |
p univariate |
Adjusted OR(95% CI) |
P multivariate |
Age (years) † |
|
|
|
|
< 41 |
34 (44) |
|
|
|
≥ 41 |
41 (47) |
0.7 |
- |
- |
Gender |
|
|
|
|
Male |
55 (45) |
|
|
|
Female |
20 (48) |
0.7 |
- |
- |
Body mass index† |
|
|
|
|
≤ 23 |
28 (48) |
0.3 |
|
|
> 23 |
25 (40) |
|
- |
- |
Baseline ALT† |
|
|
|
|
≤ 81 |
40 (43) |
|
|
|
> 81 |
35 (49) |
0.4 |
- |
- |
Injecting drug user |
|
|
|
|
Yes |
60 (44) |
|
|
|
No |
15 (52) |
0.4 |
- |
- |
CDC clinical category |
|
|
|
|
A-B |
59 (50) |
0.08 |
1.7 (0.7-3.9) |
0.1 |
C |
16 (35) |
|
|
|
Liver fibrosis |
|
|
|
|
≤ 2 |
29 (41) |
|
|
|
≥ 3 |
19 (41) |
0.9 |
- |
- |
Cirrhosis |
|
|
|
|
Yes |
11 (44) |
0.7 |
- |
- |
No |
37 (41) |
|
|
|
HCV genotype |
|
|
|
|
1-4 |
34 (33) |
|
|
|
2-3 |
41 (67) |
<0.001 |
5.4 (2.5-11.3) |
<0.001 |
Baseline HCV-RNA load (IU/mL) |
|
|
|
|
<600000 |
35 (54) |
0.06 |
1.6 (0.7-3.4) |
0.1 |
≥600000 |
39 (39) |
|
|
|
Daily dose of RBV (mg/kg) † |
|
|
|
|
< 14.8 |
32 (40) |
|
|
|
≥ 14.8 |
39 (48) |
0.3 |
- |
- |
Type of peg-IFN |
|
|
|
|
Alfa-2a |
56 (43) |
|
|
|
Alfa-2b |
19 (54) |
0.2 |
- |
- |
Initiation of peg-IFN treatment |
|
|
|
|
2001-2004 |
23 (45) |
|
|
|
2005-2008 |
52 (46) |
0.9 |
- |
- |
Exposure to HCV therapy |
|
|
|
|
< 80% |
4 (23) |
|
|
|
≥ 80% |
71 (48) |
0.05 |
4.8 (1.3-17.8) |
0.01 |
Baseline undetectable plasma HIV-RNA |
|
|
|
|
Yes |
69 (48) |
|
|
|
No |
6 (30) |
0.1 |
- |
- |
Baseline CD4 cell count/mm3† |
|
|
|
|
< 459 |
35 (42) |
|
|
|
≥ 459 |
40 (49) |
0.4 |
- |
- |
Baseline CD4 cell count/mm3 |
|
|
|
|
≥ 200 |
71 (45) |
|
|
|
< 200 |
4 (50) |
0.8 |
- |
- |
Baseline LDL-cholesterol (mg/L) |
|
|
|
|
≥ 100 |
26 (54) |
|
|
|
< 100 |
29 (40) |
0.1 |
- |
- |
Third drug in ART combination |
|
|
|
|
NVP |
40 (56) |
0.015 |
2.5 (1.2-5.0) |
0.01 |
LPV/r |
35 (37) |
|
|
|
NRTI backbone during HCV therapy |
|
|
|
|
TDF plus 3TC |
44 (42) |
|
|
|
TDF plus FTC |
31 (51) |
0.3 |
- |
- |
†Categorized by median. ALT: alanine aminotransferase. RBV: ribavirin. peg-IFN: pegylated interferon. LDL: low-density lipoprotein. ART: antiretroviral therapy. NVP:
nevirapine. LPV/r: lopinavir/ritonavir. NRTIs: nucleos (t) ide retrotranscriptase inhibitors. TDF: tenofovir. 3TC: lamivudine. FTC: emtricitabine.